Nomograms for prediction of disease recurrence in patients with primary Ta, T1 transitional cell carcinoma of the bladder

Journal of Korean Medical Science

Volumn 23, Issue 3, 2008, Pages 428-433

  Sung, Joon Hong ^a,i   Kang, Su Cho ^a   Han, Mooyoung ^a   Hyun, Yul Rhew ^b   Kim, Choung Soo ^c   Soo, Bang Ryu ^d   Chong, Koo Sul ^e   Moon, Kee Chung ^f   Tong, Choon Park ^g   Hyung, Jin Kim ^h  

^a Yonsei University   (South Korea)

^b Kosin University   (South Korea)

^c University of Ulsan   (South Korea)

^d Chonnam National University   (South Korea)

^e Chungnam National University   (South Korea)

^f Pusan National University   (South Korea)

^g Yeungnam University   (South Korea)

^h Chonbuk National University   (South Korea)

ⁱ Yonsei University College of Medicine   (South Korea)

Author keywords

Carcinoma, transitional cell; Nomograms; Recurrence; Urinary bladder

Indexed keywords

AGED; ARTICLE; BLADDER TUMOR; CARCINOMA IN SITU; DISEASE FREE SURVIVAL; FEMALE; HUMAN; MALE; MULTIVARIATE ANALYSIS; NOMOGRAM; PREDICTION AND FORECASTING; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RECURRENT DISEASE; REGRESSION ANALYSIS; REPRODUCIBILITY; TRANSITIONAL CELL CARCINOMA; VALIDATION STUDY;

AGED; CARCINOMA IN SITU; CARCINOMA, TRANSITIONAL CELL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MULTIVARIATE ANALYSIS; NOMOGRAMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECURRENCE; REGRESSION ANALYSIS; REPRODUCIBILITY OF RESULTS; URINARY BLADDER NEOPLASMS;

EID: 46849091569     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2008.23.3.428     Document Type: Article

References (23)

1. Prout GR Jr. Management (control) of early bladder lesions. Cancer Res 1977; 37: 2891-4.
2. Allard P, Bernard P, Fradet Y, Tetu B. The early clinical course of primary Ta and T1 bladder cancer: a proposed prognostic index. Br J Urol 1998; 81: 692-8.
3. Dalesio O, Schulman CC, Sylvester R, De Pauw M, Robinson M, Denis L, Smith P, Viggiano G. Prognostic factors in superficial bladder tumors. A study of the European Organization for Research on Treatment of Cancer: Genitourinary Tract Cancer Cooperative Group. J Urol 1983; 129: 730-3.
4. Kaasinen E, Rintala E, Hellstrom P, Viitanen J, Juusela H, Rajala P, Korhonen H, Liukkonen T. Factors explaining recurrence in patients undergoing chemoimmunotherapy regimens for frequently recurring superficial bladder carcinoma. Eur Urol 2002; 42: 167-74.
5. Kiemeney LA, Witjes JA, Heijbroek RP, Verbeek AL, Debruyne FM. Predictability of recurrent and progressive disease in individual patients with primary superficial bladder cancer. J Urol 1993; 150: 60-4.
6. Kurth KH, Denis L, Bouffioux C, Sylvester R, Debruyne FM, Pavone-Macaluso M, Oosterlinck W. Factors affecting recurrence and progression in superficial bladder tumours. Eur J Cancer 1995; 31A: 1840-6.
7. Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, Palou J, Algaba F, Vicente-Rodriguez J. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J Urol 2000; 164: 680-4.
8. Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, Palou J, Vicente-Rodriguez J. Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J Urol 2000; 163: 73-8.
9. Parmar MK, Freedman LS, Hargreave TB, Tolley DA. Prognostic factors for recurrence and followup policies in the treatment of superficial bladder cancer: report from the British Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party). J Urol 1989; 142: 284-8.
10. Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DW, Kurth K. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006; 49: 466-5.
11. Heney NM, Ahmed S, Flanagan MJ, Frable W, Corder MP, Hafermann MD, Hawkins IR. Superficial bladder cancer: progression and recurrence. J Urol 1983; 130: 1083-6.
12. Kiemeney LA, Witjes JA, Heijbroek RP, Koper NP, Verbeek AL, Debruyne FM. Should random urothelial biopsies be taken from patients with primary superficial bladder cancer? A decision analysis. Members of the Dutch South-East Co-Operative Urological Group. Br J Urol 1994; 73: 164-71.
13. Loening S, Narayana A, Yoder L, Slymen D, Penick G, Culp D. Analysis of bladder tumor recurrence in 178 patients. Urology 1980; 16: 137-41.
14. Mulders PF, Meyden AP, Doesburg WH, Oosterhof GO, Debruyne FM. Prognostic factors in pTa-pT1 superficial bladder tumours treated with intravesical instillations. The Dutch South-Eastern Urological Collaborative Group. Br J Urol 1994; 73: 403-8.
15. Narayana AS, Loening SA, Slymen DJ, Culp DA. Bladder cancer: factors affecting survival. J Urol 1983; 130: 56-60.
16. Pawinski A, Sylvester R, Kurth KH, Bouffioux C, van der Meijden A, Parmar MK, Bijnens L. A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council Working Party on Superficial Bladder Cancer. J Urol 1996; 156: 1934-40.
17. Shinka T, Matsumoto M, Ogura H, Hirano A, Ohkawa T. Recurrence of primary superficial bladder cancer treated with prophylactic intravesical Tokyo 172 bacillus Calmette-Guerin: a long-term follow-up. Int J Urol 1997; 4: 139-43.
18. Witjes JA, Kiemeney LA, Schaafsma HE, Debruyn FM. The influence of review pathology on study outcome of a randomized multicentre superficial bladder cancer trial. Members of the Dutch South East Cooperative Urological Group. Br J Urol 1994; 73: 172-6.
19. Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, Morrow M. AJCC Cancer Staging Manual. 6th ed. New York: Springer Verlag; 2002; Pages.
20. Wan J, Grossman HB. Bladder carcinoma in patients age 40 years or younger. Cancer 1989; 64: 178-81.
21. Linn JF, Sesterhenn I, Mostofi FK, Schoenberg M. The molecular characteristics of bladder cancer in young patients. J Urol 1998; 159: 1493-6.
22. Shariat SF, Zippe C, Ludecke G, Boman H, Sanchez-Carbayo M, Casella R, Mian C, Friedrich MG, Eissa S, Akaza H, Sawczuk I, Serretta V, Huland H, Hedelin H, Rupesh R, Miyanaga N, Sagalowsky AI, Wians F Jr, Roehrborn CG, Lotan Y, Perrotte P, Benayoun S, Marberger MJ, Karakiewicz PI. Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder. J Urol 2005; 173: 1518-25.
23. Kattan MW, Reuter V, Motzer RJ, Katz J, Russo P. A postoperative prognostic nomogram for renal cell carcinoma. J Urol 2001; 166: 63-7.